Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial

OBJECTIVE: This study evaluated the safety and preliminary efficacy of vorolanib, a novel tyrosine kinase inhibitor, for treatment of patients with advanced solid tumors. METHODS: During dose escalation, patients received increasing doses of oral vorolanib (50−250 mg once daily) in cycles of four we...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Chin J Cancer Res
Hlavní autoři: Song, Yan, Wang, Jinwan, Ren, Xiubao, Jin, Jie, Mao, Li, Liang, Chris, Ding, Lieming, Yang, Lin
Médium: Artigo
Jazyk:Inglês
Vydáno: AME Publishing Company 2021
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7941683/
https://ncbi.nlm.nih.gov/pubmed/33707933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2021.01.11
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky